Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 24

  • 741 clinical trials
  • 263 recruiting
  • 237 conditions
  • 26 countries

Conditions in this area

237 conditions with trials, the busiest first

Obesity116Type 2 diabetes mellitus83Overweight51Type 1 diabetes mellitus38Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis22Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic foot13Diabetic retinal oedema13Diabetic neuropathy12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Dyslipidaemia8Iron deficiency8Phenylketonuria8+213

Clinical trials in Metabolism and nutrition disorders

741 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

741 clinical trials

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Oral Orforglipron vs Weekly Dulaglutide in Children and Adolescents (10‑<18 years) with Type 2 Diabetes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus+2

Not yet recruiting

Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Obesity

Not yet recruiting

A study of NNC0638-0355 to evaluate safety, tolerability and weight loss with multiple doses in adults with obesity or overweight

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:Novo Nordisk A/S

Obesity

Not yet recruiting

Phase 2b Randomized Study of Semaglutide Subcutaneous Depot for Weight Reduction in Adults with Obesity or Overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Camurus AB

Infertility+1

Not yet recruiting

Effect of Semaglutide on Sperm Concentration in Overweight Infertile Men: A Randomized Placebo‑Controlled Trial

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:Region Hovedstaden

Gaucher's disease type III

Not yet recruiting

Efficacy and safety of oral venglustat versus intravenous imiglucerase in children aged 2‑11 years with Gaucher disease type 3

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Imiglucerase
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cushing's syndrome

Not yet recruiting

Efficacy and safety of osilodrostat with drug combination in patients with hypertension caused by Cushing's syndrome

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Recordati AG

Monogenic diabetes

Not yet recruiting

Effect of semaglutide added to sulfonylurea on blood sugar in adults with HNF1A‑MODY and HNF4A‑MODY

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Steno Diabetes Center Copenhagen

Gaucher's disease type I

Not yet recruiting

Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients with Gaucher Disease Type 1 Using Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Spur Therapeutics Limited

Adrenal insufficiency

Not yet recruiting

Oral bioavailability and tolerability of hydrocortisone tablets vs hydrocortisone sodium phosphate orodispersible films in children and adolescents with adrenal insufficiency

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Hydrocortisone
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Fabry's disease

Not yet recruiting

Efficacy and Safety of Lucerastat in Treatment‑Naïve Adult Male Patients with Fabry Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Lucerastat
  • Sponsor:Idorsia Pharmaceuticals Ltd.

Acromegaly

Not yet recruiting

Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pasireotide
  • Sponsor:Instituto De Investigacion En Ciencias De La Salud Germans Trias I Pujol

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide76 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsTirzepatide13 clinical trialsParacetamol12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.